Analysis of Circulating Tumor Cells in Breast Cancer

View More View Less
  • a From Departments of Medical Oncology and Therapeutic Research and Hematology and Hematopoietic Cell Transplantation, City of Hope Cancer Center, Duarte, California.
Restricted access

Over the past few decades, substantial progress has been made in the diagnosis and treatment of breast cancer. Early identification of relapsed and metastatic disease has been a primary focus of ongoing research. Circulating tumor cells (CTCs) are implicated as harbingers of metastases. With advances in detection technologies, CTCs offer the option for real-time liquid biopsies. Methods to identify CTCs in the bloodstream by physical or biochemical properties, although feasible, still require improvements to promote widespread, reproducible use. Sufficient data support enumeration and assessment of changes in the number of CTCs as prognostic indicators, but controversy around their predictive utility for selecting treatments remains. As the technology to detect CTCs and characterize their heterogeneous molecular profile evolves, additional information will likely be obtained to guide targeted and individualized therapies.

Correspondence: George Somlo, MD, City of Hope Cancer Center, 1500 East Duarte Road, Duarte, CA 91010. E-mail: gsomlo@coh.org
  • 1.

    Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012;62:1029.

  • 2.

    Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aus Med J 1869;14:146149.

    • Search Google Scholar
    • Export Citation
  • 3.

    Hsieh HB, Somlo G, Liu X. Location and biomarker characterization of circulating tumor cells. In: Herold K, Rasooly A, eds. Biosensors and Molecular Technologies for Cancer Diagnostics. Boca Raton, FL: CRC Press; 2012:257275.

    • Search Google Scholar
    • Export Citation
  • 4.

    Gerber B, Krause A, Muller H. Simultaneous immunohistochemical detection of tumor cells in lymph node and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001;19:960971.

    • Search Google Scholar
    • Export Citation
  • 5.

    Pantel K, Schlimok G, Angstwurm M. Methodological analysis of immunohistochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994;3:165173.

    • Search Google Scholar
    • Export Citation
  • 6.

    Sieuwerts AM, Kraan J, Bolt J. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101:6166.

    • Search Google Scholar
    • Export Citation
  • 7.

    Kasimir-Bauer S, Hoffmann O, Wallwiener D. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012;14:R15.

    • Search Google Scholar
    • Export Citation
  • 8.

    Riethdorf S, Fritsche H, Muller V. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920928.

    • Search Google Scholar
    • Export Citation
  • 9.

    Joosse S, Hannemann J, Spötter J. Changes in keratin expression during metastatic progression of breast cancer: impact on detection of circulating tumor cells. Clin Cancer Res 2012;18:9931003.

    • Search Google Scholar
    • Export Citation
  • 10.

    Ross J, Slodlowska EA. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 2009;132:237245.

  • 11.

    Fehm T, Hoffmann O, Aktas B. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009;11:R59.

    • Search Google Scholar
    • Export Citation
  • 12.

    Coumans F, Ligthart S, Uhr J. Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res 2012;18:57115718.

  • 13.

    Eifler RL, Lind J, Falkenhagen D. Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry B Clin Cytom 2011;80:100111.

    • Search Google Scholar
    • Export Citation
  • 14.

    Yu M, Stott S, Toner M. Circulating tumor cells: approaches to isolation and characterization. J Cell Bio 2011;192:373382.

  • 15.

    Mikolajczyk SD, Millar LS, Tsinberg D. Detection of EpCAM negative and cytokeratin negative circulating tumor cells in peripheral blood. J Oncol 2011;2011:252361.

    • Search Google Scholar
    • Export Citation
  • 16.

    Madhavan D, Zucknick M, Wallwiener M. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 2012;18:59725982.

    • Search Google Scholar
    • Export Citation
  • 17.

    Harris L, Fritsche H, Mennel R. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:52875312.

    • Search Google Scholar
    • Export Citation
  • 18.

    Stathopoulou A, Vlachonikolis I, Mavroudis D. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002;20;34043412.

    • Search Google Scholar
    • Export Citation
  • 19.

    Xenidis N, Perraki M, Kafousi M. Predictive and prognostic value of peripheral blood cytokeratin 19 mRNA positive cells detected by real time polymerase chain reaction in node negative breast cancer patients. J Clin Oncol 2006;24;37563762.

    • Search Google Scholar
    • Export Citation
  • 20.

    Pierga JY, Bidard FC, Mathiot C. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008;14:70047010.

    • Search Google Scholar
    • Export Citation
  • 21.

    Lucci A, Hall CS, Lodhi AK. Circulating tumour cells in nonmetastatic breast cancer: a prospective study. Lancet Oncol 2012;13:688695.

  • 22.

    Bidard FC, Delaloge S, Giacchetti S. Long term independent prognostic impact of circulating tumor cells detected before neoadjuvant chemotherapy in non-metastatic breast cancer: 70 months analysis of the REMAGUS02 study [abstract]. Cancer Res 2012;72(24 Suppl):Abstract P2-01-04.

    • Search Google Scholar
    • Export Citation
  • 23.

    Zhang L, Riethdorf S, Wu G. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012;18:57015710.

    • Search Google Scholar
    • Export Citation
  • 24.

    Xenidis N, Perraki M, Apostolaki S. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br J Cancer 2013;108:549556.

    • Search Google Scholar
    • Export Citation
  • 25.

    Hayes DF, Cristofanilli M, Budd GT. Circulating tumor cells at each follow up time point during therapy of metastatic breast cancer patients predict progression free and overall survival. Clin Cancer Res 2006;12:42184224.

    • Search Google Scholar
    • Export Citation
  • 26.

    Budd GT, Cristofanilli M, Ellis MJ. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:64036409.

    • Search Google Scholar
    • Export Citation
  • 27.

    Pierga JY, Hajage D, Bachelot T. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012;23:618624.

    • Search Google Scholar
    • Export Citation
  • 28.

    De Giorgi U, Valero V, Rohren E. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 2010;21:3339.

    • Search Google Scholar
    • Export Citation
  • 29.

    Cristofanilli M, Broglio KR, Guarneri V. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 2007;7:471479.

    • Search Google Scholar
    • Export Citation
  • 30.

    Liu MC, Shields PG, Warren RD. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27:51535159.

    • Search Google Scholar
    • Export Citation
  • 31.

    Giordano A, Egleston BL, Hajage D. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res 2013;19:15961602.

    • Search Google Scholar
    • Export Citation
  • 32.

    Pierga JY, Hajage D, Bachelot T. Prognostic value of circulating tumor cells count at progressive disease after first line chemotherapy metastatic breast patients in a large prospective multicenter trial including serum tumor markers (IC 2006-04 study) [abstract]. Cancer Res 2012;72(24 Suppl):Abstract P2-01-13.

    • Search Google Scholar
    • Export Citation
  • 33.

    Punnoose EA, Atwal SK, Spoerke JM. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010;5:e1251.

  • 34.

    Giordano A, Giuliano M, De Laurentis M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012;23:11441150.

    • Search Google Scholar
    • Export Citation
  • 35.

    Giuliano M, Giordano A, Jackson S. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011;13:R67.

    • Search Google Scholar
    • Export Citation
  • 36.

    Munzone E, Botteri E, Sandri MT. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer 2012;12:340346.

    • Search Google Scholar
    • Export Citation
  • 37.

    Giordano A, Barnato S, Giuliano M. Effect of targeted therapy on circulating tumor cells in patients with metastatic breast cancer [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 3.

    • Search Google Scholar
    • Export Citation
  • 38.

    Wallwiener M, Hartkopf A, Baccelli I. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013;137:503510.

    • Search Google Scholar
    • Export Citation
  • 39.

    Azim HA Jr, Rothe F, Aura CM. Correlation between circulating tumor cells (CTCs), PET/CT response and pathological and complete response (pCR) in primary HER2-positive (HER2+) breast cancer patients: a substudy from the NeoALTTO trial [abstract]. Ann Oncol 2012;23(Suppl 9):Abstract 2467.

    • Search Google Scholar
    • Export Citation
  • 40.

    Somlo G, Lau SK, Frankel P. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 2011;128:155163.

    • Search Google Scholar
    • Export Citation
  • 41.

    Pestrin M, Bessi S, Galardi F. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009;118:523530.

    • Search Google Scholar
    • Export Citation
  • 42.

    Fehm T, Becker S, Duerr-Stoerzer S. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007;9:R74.

    • Search Google Scholar
    • Export Citation
  • 43.

    Jaeger B, Rack B, Neugebauer J. HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: results of the German SUCCESS B trial [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 10540.

    • Search Google Scholar
    • Export Citation
  • 44.

    Hayashi N, Nakamura S, Tokuda Y. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 2012;17:96104.

    • Search Google Scholar
    • Export Citation
  • 45.

    Pestrin M, Bessi S, Puglisi F. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 2012;134:283289.

    • Search Google Scholar
    • Export Citation
  • 46.

    Gazzaniga P, Naso G, Gradilone A. Chemosensitivity profile assay of circulating cancer cells (CTCs): prognostic and predictive value in epithelial tumors. Int J Cancer 2010;126):24372447.

    • Search Google Scholar
    • Export Citation
  • 47.

    Gradilone A, Naso G, Raimondi C. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011;22:8692.

    • Search Google Scholar
    • Export Citation
  • 48.

    Papadaki MA, Kallergi G, Mavroudis D. Effect of first-line chemotherapy in the expression of stemness and epithelial-to-mesenchymal transition markers in circulating tumor cells of patients with metastatic breast cancer [abstract]. Cancer Res 2012;72(24 Suppl):Abstract P2-01-07.

    • Search Google Scholar
    • Export Citation
  • 49.

    Chaffer CL, Brueckmann I, Scheel C. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011;108:79507955.

    • Search Google Scholar
    • Export Citation
  • 50.

    Giordano A, Gao H, Anfossi S. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 2012;11:25262534.

    • Search Google Scholar
    • Export Citation
  • 51.

    Yu M, Bardia A, Wittner B. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580584.

    • Search Google Scholar
    • Export Citation
  • 52.

    Olaussen KA, Dunant A, Fouret P. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983991.

    • Search Google Scholar
    • Export Citation
  • 53.

    Riess J, Das M, Frankel P. Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 10574.

    • Search Google Scholar
    • Export Citation
  • 54.

    Kallergi G, Agelaki S, Kalykaki A. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 2008;10:80.

    • Search Google Scholar
    • Export Citation
  • 55.

    Xu X, Shen Y, Dewitt W. Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 10516.

    • Search Google Scholar
    • Export Citation
  • 56.

    Yang L, Wang Y, Chu P. Identification of p53 mutation in whole genome DNA from single circulating tumor cells (CTCs) and primary breast cancers (BC) from patients (pts) with metastatic breast cancer (MBC) [abstract]. Cancer Res 2012:71(24 Suppl):Abstract P4-07-12.

    • Search Google Scholar
    • Export Citation
  • 57.

    Powell A, Talasaz AH, Zhang H. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012;7:e33788.

    • Search Google Scholar
    • Export Citation
  • 58.

    Mostert B, Sieuwerts A, Kraan J. Gene expression profiles of circulating tumor cells in metastatic breast cancer patients [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 10504.

    • Search Google Scholar
    • Export Citation
  • 59.

    Magbanua MJ, Sosa EV, Roy R. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res 2013;73:3040.

    • Search Google Scholar
    • Export Citation
  • 60.

    Dawson SJ, Tsui D, Murtaza M. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:11991209.

  • 61.

    Camara O, Rengsberger M, Egbe A. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 2007;18:14841492.

    • Search Google Scholar
    • Export Citation
  • 62.

    Pachmann K, Camara O, Kavallaris A. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008;26:12081215.

    • Search Google Scholar
    • Export Citation
  • 63.

    Franken B, de Groot MR, Mastboom WJ. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res 2012;14:R133.

    • Search Google Scholar
    • Export Citation
  • 64.

    Muller V, Riethdorf S, Rack B. Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012;14:R118.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 271 156 10
PDF Downloads 36 27 0
EPUB Downloads 0 0 0